AAM comments on Amneal's U.S. expansion of end-to-end biosimilars development with their acquisition of Kashiv BioSciences
Adds Chicago research and development facility, New Jersey manufacturing site
The Biosimilars Council
The Biosimilars Council and AAM applaud senate markup and committee passage of the expedited access to Biosimilars Act
Legislation codifies FDA's science-based approach to biosimilar review by limiting comparative efficacy studies; Introduced and passed House Committee this week.
AAM, Biosimilars Council praise House action on biosimilar bills
Legislative progress codifies FDA's science-based approach to biosimilar review by limiting comparative efficacy studies; Eliminates arbitrary distinction between interchangeable biologics and biosimilars.
Groups join the Biosimilars Council and AAM letter of support for interchangeability legislation
39 Groups support the Biosimilar Red Tape Elimination Act.
Report: A decade of biosimilars and barriers remain
Matrix Global Advisors report highlights current barriers and recommendations for robust competition and patient savings in the next decade.